Production of a certain product in two different countries...

Name: Problem 2, Chapter 22: Basic statistics and Pharmaceutical Statistical Applications
Uploaded: 2024-01-04T14:56:55-08:00
Channel: Shu Naito
Description: Production of a certain product in two different countries (A and B) were compared to the manufacturer's original production site (standard). Dissolution data is presented in Table 22.6 and Figure 22.6. Visually it appears that site B has a profile closer to the reference standard, but do both of the foreign facilities meet the SUPAC-IR guidelines for similarity?

Production of a certain product in two different countries (A and B) were compared to the manufacturer's original production site (standard). Dissolution data is presented in Table 22.6 and Figure 22.6. Visually it appears that site B has a profile closer to the reference standard, but do both of the foreign facilities meet the SUPAC-IR guidelines for similarity?

Labs

Want to see this concept in action?

NEW

Explore this concept interactively to see how it behaves as you change inputs.

View Labs

Key Concepts

Dissolution Testing

Dissolution testing is a critical quality control measure in pharmaceutical development that assesses how quickly and efficiently a drug is released from its dosage form into a solution under standardized conditions. It provides insight into the bioavailability of the drug and plays a key role in ensuring that the product will perform as expected in the body.

Similarity Factor (f2)

The similarity factor, commonly known as f2, is a statistical tool used to compare the dissolution profiles of two drug products. It quantifies the similarity between a test product's release profile and that of a reference product, with guidelines typically setting a benchmark (for example, an f2 value between 50 and 100) to determine whether the profiles are sufficiently similar for regulatory purposes.

SUPAC-IR Guidelines

The SUPAC-IR (Scale-Up and Post-Approval Changes for Immediate Release products) guidelines are regulatory recommendations that outline the criteria for making manufacturing changes after the initial approval of a drug. These guidelines help manufacturers ensure that any variations in product production, such as changes in production sites or processes, do not adversely affect the drug's quality, efficacy, or safety, particularly as reflected in its dissolution behavior.

Transcript

Please give Ace some feedback